A lower ALC/AMC ratio is associated with poor prognosis of peripheral T-cell lymphoma-not otherwise specified. (October 2018)

• Record Type: Journal Article
• Authors: Li, Qian; Gao, Shuang; Ma, Jing; Liu, Su; Yue, Yuanfang; Chen, Lin; Li, Han; Wang, Xue; Li, Dongying; Cao, Zeng; Zhao, Zhigang; Wang, Xiaofang; Yu, Yong; Zhang, Yizhuo; Wang, Yafei
• Is Part Of: Leukemia research. Volume 73(2018)
• Page Start: 5
• Page End: 11
• Publication Date: 2018-10
• Subjects: PTCLs Peripheral T cell lymphomas -- NHL non-Hodgkin lymphomas -- PTCL-NOS peripheral T-cell lymphoma-not otherwise specified -- AITL angioimmunoblastic T - cell lymphoma -- ATLL adult T - cell leukemia/lymphoma -- ALCL anaplastic large cell lymphoma -- LDH lactate dehydrogenase -- CBC complete blood count; Peripheral T-cell lymphoma-not otherwise specified -- Absolute lymphocyte count -- ALC/AMC ration -- Prognosis; Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2018.07.020
• Languages: English
• ISSNs: 0145-2126

Abstract

Highlights: The ALC/AMC ratio is positively correlated with survival of PTCL-NOS patients. The ALC/AMC ratio is an independent prognostic factor predicting survival. The ALC/AMC ratio combined with PTCL-U score may be a better guide for the prognosis of PTCL-NOS patients. Abstract: Peripheral T-cell lymphomas-not otherwise specified (PTCL-NOS) generally have poor patient outcomes, with a 5-year survival rate of ∼32%. The most common prognostic system for patients with PTCL-NOS, the PTCL-U score, is often inadequate because it does not take into consideration the role of host immunity or the microenvironment induced by the tumor. In this paper we aimed to determine the correlation between the Absolute Lymphocyte Count/Absolute Monocyte Count (ALC/AMC) ratio and the prognosis of PTCL-NOS. Retrospective data from 58 patients diagnosed with PTCL-NOS were analyzed. We found that PTCL-NOS patients with lower ALC/AMC ratios (ALC/AMC < 2) had shorter overall survival (OS) and progression-free survival (PFS) periods (OS: P < 0.001; PFS: P = 0.001) compared with other patients (ALC/AMC ≥ 2). When we combined ALC/AMC ratio and PTCL-U scores, patients could be clearly divided into 3 groups with significantly different prognoses. This study suggests that the ALC/AMC ratio may be a simple, effective, and independent prognostic factor for OS and PFS, and may be helpful to identify high-risk PTCL-NOS patients. Since the ALC/AMC ratio is related to host immunity and tumor microenvironment and reflects immune status and individual differences, combining ALC/AMC with PTCL-U may be a better prognostic guide for PTCL-NOS patients.